396 related articles for article (PubMed ID: 29684967)
1. [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics].
Bae JH; Yang DH
Korean J Gastroenterol; 2018 Apr; 71(4):192-195. PubMed ID: 29684967
[TBL] [Abstract][Full Text] [Related]
2. The biologics of ulcerative colitis.
Macaluso FS; Renna S; Orlando A; Cottone M
Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
[TBL] [Abstract][Full Text] [Related]
3. Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study.
Barberio B; Zingone F; Frazzoni L; D'Incà R; Maccarone MC; Ghisa M; Massimi D; Lorenzon G; Savarino EV
Dig Dis; 2021; 39(1):16-24. PubMed ID: 32450562
[TBL] [Abstract][Full Text] [Related]
4. [Golimumab Therapy in Ulcerative Colitis].
Moon W
Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
[TBL] [Abstract][Full Text] [Related]
5. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
[TBL] [Abstract][Full Text] [Related]
6. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
[TBL] [Abstract][Full Text] [Related]
7. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
8. Positioning Therapy for Ulcerative Colitis.
Grinspan A; Kornbluth A
Curr Gastroenterol Rep; 2015 Aug; 17(8):29. PubMed ID: 26143627
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
[No Abstract] [Full Text] [Related]
10. Biologic Therapy for Ulcerative Colitis.
Bhattacharya A; Osterman MT
Gastroenterol Clin North Am; 2020 Dec; 49(4):717-729. PubMed ID: 33121691
[TBL] [Abstract][Full Text] [Related]
11. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
Farkas K; Rutka M; Golovics PA; Végh Z; Lovász BD; Nyári T; Gecse KB; Kolar M; Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Malickova K; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Palatka K; Lakatos PL; Lukas M; Molnár T
J Crohns Colitis; 2016 Nov; 10(11):1273-1278. PubMed ID: 27106537
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
[TBL] [Abstract][Full Text] [Related]
14. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Jung YS; Han M; Park S; Cheon JH
Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
[TBL] [Abstract][Full Text] [Related]
15. An update on anti-TNF agents in ulcerative colitis.
Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
[TBL] [Abstract][Full Text] [Related]
16. Special considerations for biologic medications in pediatric ulcerative colitis.
Jerger L; Hyams JS
Expert Opin Biol Ther; 2020 Apr; 20(4):429-435. PubMed ID: 31652087
[No Abstract] [Full Text] [Related]
17. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
[TBL] [Abstract][Full Text] [Related]
18. Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis.
Morita Y; Bamba S; Takahashi K; Imaeda H; Nishida A; Inatomi O; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
Scand J Gastroenterol; 2016 Aug; 51(8):934-41. PubMed ID: 26888161
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy options for ulcerative colitis.
Chaparro M; Gisbert JP
Expert Opin Pharmacother; 2016 Jul; 17(10):1339-49. PubMed ID: 27240112
[TBL] [Abstract][Full Text] [Related]
20. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]